Material Agreement Form 8 K

On November 1, 2024, Kiromic BioPharma, Inc. (the "Company") entered into an Exchange Agreement (the "Exchange Agreement") with the holder of promissory notes of the Company (the "Holder") pursuant to which the Holder agreed to exchange aggregate principal amount of $2.4 million of the Company's 25% Senior Secured Convertible Promissory Notes (the "Exchange Notes") plus accrued interest for 3,000 shares of Series E Convertible Voting Preferred Stock (the "Series E Preferred Stock").

The foregoing description of the Exchange Agreement is qualified in its entirety by reference to the full text of such Exchange Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.